Introduction of Z-GP scaffold into procarbazine reduces spermatoxicity and myelosuppression.

Graphical abstract Highlights • Z-GP-Pcb has been designed and synthesized with an overall yield of 32.7%. • Z-GP-Pcb targets to FAPα. • Z-GP-Pcb shows less spermatoxicity than Pcb. • Z-GP-Pcb demonstrates less myelosuppression than Pcb. Abstract Incorporation of carbobenzoxy-glycylprolyl (Z-GP) to either α or β position of the hydrazine moiety in procarbazine (Pcb) has been carried on in 5-steps process. The overall yield was 32.7%. The new entity Z-GP-Pcb was confirmed targeting to fibroblast activation protein-α (FAPα). Z-GP-Pcb may be hydrolyzed by either isolated rhFAPα or tumor homogenate. It was shown far less cytotoxicity against NCI-H460 cell line than Pcb. Z-GP-Pcb was displayed the potency to reduce spermatoxcity in H22-bearing mice. The mechanism may be ascribed to the blockade of dehydrogenation by α-glycerolphosphate dehydrogenase. This candidate was further proved equal antitumor activity to Pcb. However, the introduction of Z-GP scaffold decreased myelosuppression. All the evidences support that Z-GP-Pcb is a better antitumor agent than Pcb. [ABSTRACT FROM AUTHOR]